Resumen
Current guidelines suggest that polycythemia vera (PV) patients maintain a strict hematocrit less than 45%. However, to date, little is known about the relationship between HCT control and PV- related symptom burden. In this study, PV patient data was analyzed from the CYTO PV trial (n = 224) and the MPN-SAF study cohort (n = 645). No significant differences in symptom burden were seen at the 6 and 12 month follow-up when evaluating prospective hematocrit control in the CYTO PV cohort. Patients in the MPN-SAF cohort with a worst item score of greater than 5/10 on the Myeloproliferative Neoplasm Symptom Total Symptom Score had a significantly lower mean hematocrit (p =.0376). These findings suggest a relationship between traditional aggressive therapy for PV and increased symptom burden with prolonged therapy. Thus, symptom burden should be considered when contemplating the choice of therapy in the second-line setting for PV.
Idioma original | English (US) |
---|---|
Páginas (desde-hasta) | 1481-1487 |
Número de páginas | 7 |
Publicación | Leukemia and Lymphoma |
Volumen | 58 |
N.º | 6 |
DOI | |
Estado | Published - jun 3 2017 |
Publicado de forma externa | Sí |
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research